References
- ZhangLTLeeSWParkKMulticenter, prospective, comparative cohort study evaluating the efficacy and safety of alfuzosin 10 mg with regard to blood pressure in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia with or without antihypertensive medicationsClin Interv Aging20151027728625653511
- SohnJTDingXMcCuneDFPerezDMMurrayPAFentanyl attenuates alpha1B-adrenoceptor-mediated pulmonary artery contractionAnesthesiology200510332733416052115
- SchwinnDARoehrbornCGAlpha1-adrenoceptor subtypes and lower urinary tract symptomsInt J Urol20081519319918304211
- SatoSHatanakaTYuyamaHTamsulosin potently and selectively antagonizes human recombinant α(1A/1D)-adrenoceptors: slow dissociation from the α(1A)-adrenoceptor may account for selectivity for α(1A)-adrenoceptor over α(1B)-adrenoceptor subtypeBiol Pharm Bull201235727722223340
- YamadaSItoYTsukadaHα1-Adrenoceptors and muscarinic receptors in voiding function – binding characteristics of therapeutic agents in relation to the pharmacokineticsBr J Clin Pharmacol20117220521721265873
- YoshidaMKudohJHommaYKawabeKSafety and efficacy of silodosin for the treatment of benign prostatic hyperplasiaClin Interv Aging2011616117221753871
- SchwinnDAPriceDTNarayanPAlpha1-adrenoceptor subtype selectivity and lower urinary tract symptomsMayo Clin Proc2004791423143415544022
- YamadaSItoYα(1)-adrenoceptors in the urinary tractHandb Exp Pharmacol201120228330621290232
- LeporHKazzaziADjavanBα-blockers for benign prostatic hyperplasia: the new eraCurr Opin Urol20122271522080875
- KojimaYSasakiSKubotaYExpression of alpha1-adrenoceptor subtype mRNA as a predictor of the efficacy of subtype selective alpha1-adrenoceptor antagonists in the management of benign prostatic hyperplasiaJ Urol20081791040104618206918
- de MeyCAlpha(1)-blockers for BPH: are there differences?Eur Urol199936Suppl 3526310559631
- CapitanioUSaloniaABrigantiAMontorsiFSilodosin in the management of lower urinary tract symptoms as a result of benign prostatic hyperplasia: who are the best candidates?Int J Clin Pract20136754455123409749
- van KerrebroeckPJardinALavalKUvan CanghPEfficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study GroupEur Urol20003730631310720857
References
- WeberMASchiffrinELWhiteWBClinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of HypertensionJ Clin Hypertens2014161426
- OelkeMBachmannADescazeaudAEAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstructionEur Urol20136411814023541338
- McVaryKTRoehrbornCGAvinsALUpdate on AUA guideline on the management of benign prostatic hyperplasiaJ Urol20111851793180321420124
- AUA Practice Guidelines CommitteeAUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendationsJ Urol200317053054712853821
- HargreaveTBMcNeillASAcute urinary retention in men: the risks and outcomes with medical therapyCurr Urol Rep2005626327015978225
- HatanoATakahashiHTamakiMPharmacological evidence of distinct alpha 1-adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral arteryBr J Pharmacol19941137237287858860
- ChappleCRA comparison of varying alpha-blockers and other pharmacotherapy options for lower urinary tract symptomsRev Urol20057Suppl 4S22S3016986051
- SchwinnDAMichelottiGAAlpha1-adrenergic receptors in the lower urinary tract and vascular bed: potential role for the alpha1d subtype in filling symptoms and effects of ageing on vascular expressionBJU Int200085Suppl 261110781179
- KeatingGMSilodosin: a review of its use in the treatment of the signs and symptoms of benign prostatic hyperplasiaDrugs20157520721725575983
- HellstromWJSikkaSCEffects of acute treatment with tamsulosin versus alfuzosin on ejaculatory function in normal volunteersJ Urol20061761529153316952675
- AnderssonKEWyllieMGEjaculatory dysfunction: why all alpha-blockers are not equalBJU Int20039287687714632836
- HofnerKJonasUAlfuzosin: a clinically uroselective alpha1-blockerWorld J Urol20021940541212022709
- AnderssonKEThe concept of uroselectivityEur Urol199833Suppl 27119556190
- McKeageKPloskerGLAlfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasiaDrugs20026263365311893233
- van KerrebroeckPJardinALavalKUEfficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study GroupEur Urol20003730631310720857
- OelkeMGerickeAMichelMCCardiovascular and ocular safety of alpha1-adrenoceptor antagonists in the treatment of male lower urinary tract symptomsExpert Opin Drug Saf2014131187119725073735